{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T02:04:51Z","timestamp":1766023491592,"version":"3.48.0"},"reference-count":33,"publisher":"e-Century Publishing Corporation","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Cancer Res"],"DOI":"10.62347\/fgly8019","type":"journal-article","created":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T04:18:11Z","timestamp":1748578691000},"page":"2056-2076","source":"Crossref","is-referenced-by-count":0,"title":["Impacts of BRCA mutations and clinical factors on niraparib efficacy in patients with platinum-sensitive recurrent ovarian cancer: a retrospective study"],"prefix":"10.62347","volume":"15","author":[{"given":"Zheyu","family":"Hu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"48694","published-online":{"date-parts":[[2025]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.1001\/jama.2024.21908","article-title":"Endometriosis and ovarian cancer","volume":"332","author":"KL","year":"2024","unstructured":"Terry KL, Harris HR and Missmer SA. Endometriosis and ovarian cancer. JAMA 2024; 332: 2116-2117.","journal-title":"JAMA"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I and Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2024; 74: 229-263.","journal-title":"CA Cancer J Clin"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"5676","DOI":"10.3390\/cancers15235676","article-title":"Characteristics, treatment patterns and survival of international federation of gynecology and obstetrics stage IV epithelial ovarian cancer-a population-based study","volume":"15","author":"Jakob","year":"2023","unstructured":"Jakob D, Schmoor C, Reuten R, Frevert ML, Dannehl D, Jansen L, Hermann S, Jungmann P, Hartkopf AD, Juhasz-Böss I and Taran FA. Characteristics, treatment patterns and survival of international federation of gynecology and obstetrics stage IV epithelial ovarian cancer-a population-based study. Cancers (Basel) 2023; 15: 5676.","journal-title":"Cancers (Basel)"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Webb K, Sharpe L, Russell H and Shaw J. Fear of cancer recurrence in ovarian cancer caregivers: a qualitative study. Psychooncology 2024; 33: e6255.","DOI":"10.1002\/pon.6255"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Zhu Q, Liu J, Xie Y and Wu C. CD1a affects the recurrence and prognosis of ovarian cancer. J Obstet Gynaecol Res 2025; 51: e16120.","DOI":"10.1111\/jog.16120"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1056\/NEJMoa2309169","article-title":"Mirvetuximab soravtansine in FRα-positive, platinum-resistant ovarian cancer","volume":"389","author":"KN","year":"2023","unstructured":"Moore KN, Angelergues A, Konecny GE, García Y, Banerjee S, Lorusso D, Lee JY, Moroney JW, Colombo N, Roszak A, Tromp J, Myers T, Lee JW, Beiner M, Cosgrove CM, Cibula D, Martin LP, Sabatier R, Buscema J, Estévez-García P, Coffman L, Nicum S, Duska LR, Pignata S, Gálvez F, Wang Y, Method M, Berkenblit A, Bello Roufai D and Van Gorp T; Gynecologic Oncology Group Partners and the European Network of Gynaecological Oncological Trial Groups. Mirvetuximab soravtansine in FRα-positive, platinum-resistant ovarian cancer. N Engl J Med 2023; 389: 2162-2174.","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/s41571-024-00888-w","article-title":"Mirvetuximab soravtansine has activity in platinum-sensitive epithelial ovarian cancer","volume":"21","author":"Romero","year":"2024","unstructured":"Romero D. Mirvetuximab soravtansine has activity in platinum-sensitive epithelial ovarian cancer. Nat Rev Clin Oncol 2024; 21: 402.","journal-title":"Nat Rev Clin Oncol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3322\/caac.21764","article-title":"Multidisciplinary considerations in the maintenance treatment of poly(ADP-ribose) polymerase inhibitors for homologous recombination-proficient, advanced-stage epithelial ovarian cancer","volume":"73","author":"Cass","year":"2023","unstructured":"Cass I, Roberts JNT, Benoit PR and Jensen NV. Multidisciplinary considerations in the maintenance treatment of poly(ADP-ribose) polymerase inhibitors for homologous recombination-proficient, advanced-stage epithelial ovarian cancer. CA Cancer J Clin 2023; 73: 8-16.","journal-title":"CA Cancer J Clin"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"3878","DOI":"10.1200\/JCO.22.01934","article-title":"Poly(ADP-ribose) polymerase inhibitors in the management of ovarian cancer: ASCO guideline rapid recommendation update","volume":"40","author":"WP","year":"2022","unstructured":"Tew WP, Lacchetti C and Kohn EC; PARP Inhibitors in the Management of Ovarian Cancer Guideline Expert Panel. Poly(ADP-ribose) polymerase inhibitors in the management of ovarian cancer: ASCO guideline rapid recommendation update. J Clin Oncol 2022; 40: 3878-3881.","journal-title":"J Clin Oncol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1200\/JCO.23.01182","article-title":"Poor concordance between cancer antigen-125 and RECIST assessment for progression in patients with platinum-sensitive relapsed ovarian cancer on maintenance therapy with a poly(ADP-ribose) polymerase inhibitor","volume":"42","author":"Tjokrowidjaja","year":"2024","unstructured":"Tjokrowidjaja A, Friedlander ML, Ledermann JA, Coleman RL, Mirza MR, Matulonis UA, Pujade-Lauraine E, Lord SJ, Scott CL, Goble S, York W and Lee CK; Gynecologic Cancer Intergroup Meta-Analysis Committee. Poor concordance between cancer antigen-125 and RECIST assessment for progression in patients with platinum-sensitive relapsed ovarian cancer on maintenance therapy with a poly(ADP-ribose) polymerase inhibitor. J Clin Oncol 2024; 42: 1301-1310.","journal-title":"J Clin Oncol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in patients with newly diagnosed advanced ovarian cancer","volume":"381","author":"Gonz&#xE1","year":"2019","unstructured":"González-Martín A, Pothuri B, Vergote I, DePont Christensen R, Graybill W, Mirza MR, McCormick C, Lorusso D, Hoskins P, Freyer G, Baumann K, Jardon K, Redondo A, Moore RG, Vulsteke C, O’Cearbhaill RE, Lund B, Backes F, Barretina-Ginesta P, Haggerty AF, Rubio-Pérez MJ, Shahin MS, Mangili G, Bradley WH, Bruchim I, Sun K, Malinowska IA, Li Y, Gupta D and Monk BJ; PRIMA\/ENGOT-OV26\/GOG-3012 Investigators. Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med 2019; 381: 2391-2402.","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"2968","DOI":"10.1200\/JCO.18.02238","article-title":"Niraparib maintenance therapy in patients with recurrent ovarian cancer after a partial response to the last platinum-based chemotherapy in the ENGOT-OV16\/NOVA trial","volume":"37","author":"Del Campo","year":"2019","unstructured":"Del Campo JM, Matulonis UA, Malander S, Provencher D, Mahner S, Follana P, Waters J, Berek JS, Woie K, Oza AM, Canzler U, Gil-Martin M, Lesoin A, Monk BJ, Lund B, Gilbert L, Wenham RM, Benigno B, Arora S, Hazard SJ and Mirza MR. Niraparib maintenance therapy in patients with recurrent ovarian cancer after a partial response to the last platinum-based chemotherapy in the ENGOT-OV16\/NOVA trial. J Clin Oncol 2019; 37: 2968-2973.","journal-title":"J Clin Oncol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1016\/S1470-2045(18)30333-4","article-title":"Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16\/NOVA): results from a double-blind, phase 3, randomised controlled trial","volume":"19","author":"AM","year":"2018","unstructured":"Oza AM, Matulonis UA, Malander S, Hudgens S, Sehouli J, Del Campo JM, Berton-Rigaud D, Banerjee S, Scambia G, Berek JS, Lund B, Tinker AV, Hilpert F, Vázquez IP, D’Hondt V, Benigno B, Provencher D, Buscema J, Agarwal S and Mirza MR. Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16\/NOVA): results from a double-blind, phase 3, randomised controlled trial. Lancet Oncol 2018; 19: 1117-1125.","journal-title":"Lancet Oncol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","article-title":"Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer","volume":"384","author":"ANJ","year":"2021","unstructured":"Tutt ANJ, Garber JE, Kaufman B, Viale G, Fumagalli D, Rastogi P, Gelber RD, de Azambuja E, Fielding A, Balmaña J, Domchek SM, Gelmon KA, Hollingsworth SJ, Korde LA, Linderholm B, Bandos H, Senkus E, Suga JM, Shao Z, Pippas AW, Nowecki Z, Huzarski T, Ganz PA, Lucas PC, Baker N, Loibl S, McConnell R, Piccart M, Schmutzler R, Steger GG, Costantino JP, Arahmani A, Wolmark N, McFadden E, Karantza V, Lakhani SR, Yothers G, Campbell C and Geyer CE Jr; OlympiA Clinical Trial Steering Committee and Investigators. Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. N Engl J Med 2021; 384: 2394-2405.","journal-title":"N Engl J Med"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1001\/jama.2017.7112","article-title":"Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers","volume":"317","author":"KB","year":"2017","unstructured":"Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips KA, Mooij TM, Roos-Blom MJ, Jervis S, van Leeuwen FE, Milne RL, Andrieu N, Goldgar DE, Terry MB, Rookus MA, Easton DF, Antoniou AC; BRCA1 and BRCA2 Cohort Consortium, McGuffog L, Evans DG, Barrowdale D, Frost D, Adlard J, Ong KR, Izatt L, Tischkowitz M, Eeles R, Davidson R, Hodgson S, Ellis S, Nogues C, Lasset C, Stoppa-Lyonnet D, Fricker JP, Faivre L, Berthet P, Hooning MJ, van der Kolk LE, Kets CM, Adank MA, John EM, Chung WK, Andrulis IL, Southey M, Daly MB, Buys SS, Osorio A, Engel C, Kast K, Schmutzler RK, Caldes T, Jakubowska A, Simard J, Friedlander ML, McLachlan SA, Machackova E, Foretova L, Tan YY, Singer CF, Olah E, Gerdes AM, Arver B and Olsson H. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA 2017; 317: 2402-2416.","journal-title":"JAMA"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1200\/JCO.2017.76.2781","article-title":"Evaluation of a streamlined oncologist-led BRCA mutation testing and counseling model for patients with ovarian cancer","volume":"36","author":"Colombo","year":"2018","unstructured":"Colombo N, Huang G, Scambia G, Chalas E, Pignata S, Fiorica J, Van Le L, Ghamande S, González-Santiago S, Bover I, Graña Suárez B, Green A, Huot-Marchand P, Bourhis Y, Karve S and Blakeley C. Evaluation of a streamlined oncologist-led BRCA mutation testing and counseling model for patients with ovarian cancer. J Clin Oncol 2018; 36: 1300-1307.","journal-title":"J Clin Oncol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"6679641","DOI":"10.1155\/2021\/6679641","article-title":"Recurrence rate and risk factors for the recurrence of ovarian endometriosis after laparoscopic ovarian cystectomy","volume":"2021","author":"Wacharachawana","year":"2021","unstructured":"Wacharachawana S, Phaliwong P, Prommas S, Smanchat B, Bhamarapravatana K and Suwannarurk K. Recurrence rate and risk factors for the recurrence of ovarian endometriosis after laparoscopic ovarian cystectomy. Biomed Res Int 2021; 2021: 6679641.","journal-title":"Biomed Res Int"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"17588359241233225","DOI":"10.1177\/17588359241233225","article-title":"Diagnostic biomarkers in ovarian cancer: advances beyond CA125 and HE4","volume":"16","author":"Ghose","year":"2024","unstructured":"Ghose A, McCann L, Makker S, Mukherjee U, Gullapalli SVN, Erekkath J, Shih S, Mahajan I, Sanchez E, Uccello M, Moschetta M, Adeleke S and Boussios S. Diagnostic biomarkers in ovarian cancer: advances beyond CA125 and HE4. Ther Adv Med Oncol 2024; 16: 17588359241233225.","journal-title":"Ther Adv Med Oncol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1002\/oby.23550","article-title":"Prediagnostic BMI trajectories in relation to pancreatic cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial","volume":"30","author":"Hoyt","year":"2022","unstructured":"Hoyt M, Song Y, Gao S, O’Palka J and Zhang J. Prediagnostic BMI trajectories in relation to pancreatic cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial. Obesity (Silver Spring) 2022; 30: 2275-2285.","journal-title":"Obesity (Silver Spring)"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.annonc.2023.05.005","article-title":"Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1\/ENGOT-ov25 trial","volume":"34","author":"Ray-Coquard I","year":"2023","unstructured":"Ray-Coquard I, Leary A, Pignata S, Cropet C, González-Martín A, Marth C, Nagao S, Vergote I, Colombo N, Mäenpää J, Selle F, Sehouli J, Lorusso D, Guerra Alia EM, Bogner G, Yoshida H, Lefeuvre-Plesse C, Buderath P, Mosconi AM, Lortholary A, Burges A, Medioni J, El-Balat A, Rodrigues M, Park-Simon TW, Dubot C, Denschlag D, You B, Pujade-Lauraine E and Harter P; PAOLA-1\/ENGOT-ov25 investigators. Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1\/ENGOT-ov25 trial. Ann Oncol 2023; 34: 681-692.","journal-title":"Ann Oncol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/j.annonc.2024.08.2241","article-title":"Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA\/ENGOT-OV26\/GOG-3012 trial","volume":"35","author":"BJ","year":"2024","unstructured":"Monk BJ, Barretina-Ginesta MP, Pothuri B, Vergote I, Graybill W, Mirza MR, McCormick CC, Lorusso D, Moore RG, Freyer G, O’Cearbhaill RE, Heitz F, O’Malley DM, Redondo A, Shahin MS, Vulsteke C, Bradley WH, Haslund CA, Chase DM, Pisano C, Holman LL, Pérez MJR, DiSilvestro P, Gaba L, Herzog TJ, Bruchim I, Compton N, Shtessel L, Malinowska IA and González-Martín A. Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA\/ENGOT-OV26\/GOG-3012 trial. Ann Oncol 2024; 35: 981-992.","journal-title":"Ann Oncol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1177\/1060028020912749","article-title":"Niraparib for the treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer","volume":"54","author":"Kerliu","year":"2020","unstructured":"Kerliu L, Myruski S, Bhatti A, Soni P, Petrosius P, Pervanas HC and Horton ER. Niraparib for the treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. Ann Pharmacother 2020; 54: 1010-1015.","journal-title":"Ann Pharmacother"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"950","DOI":"10.14740\/wjon1963","article-title":"The association of preoperative prognostic nutritional index with survival outcome in ovarian clear cell cancer","volume":"15","author":"Prueksaritanond","year":"2024","unstructured":"Prueksaritanond N, Petchsila K and Insin P. The association of preoperative prognostic nutritional index with survival outcome in ovarian clear cell cancer. World J Oncol 2024; 15: 950-959.","journal-title":"World J Oncol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.ygyno.2024.03.009","article-title":"Efficacy and safety of niraparib in patients aged 65 years and older with advanced ovarian cancer: results from the PRIMA\/ENGOT-OV26\/GOG-3012 trial","volume":"187","author":"Valabrega","year":"2024","unstructured":"Valabrega G, Pothuri B, Oaknin A, Graybill WS, Sánchez AB, McCormick C, Baurain JF, Tinker AV, Denys H, O’Cearbhaill RE, Hietanen S, Moore RG, Knudsen AØ, de La Motte Rouge T, Heitz F, Levy T, York W, Gupta D, Monk BJ and González-Martín A. Efficacy and safety of niraparib in patients aged 65 years and older with advanced ovarian cancer: results from the PRIMA\/ENGOT-OV26\/GOG-3012 trial. Gynecol Oncol 2024; 187: 128-138.","journal-title":"Gynecol Oncol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"112908","DOI":"10.1016\/j.ejca.2023.04.024","article-title":"5 years of follow-up: results from the randomised phase 3 PRIMA\/ENGOT-OV26\/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer","volume":"189","author":"Gonz&#xE1","year":"2023","unstructured":"González-Martín A, Pothuri B, Vergote I, Graybill W, Lorusso D, McCormick CC, Freyer G, Backes F, Heitz F, Redondo A, Moore RG, Vulsteke C, O’Cearbhaill RE, Malinowska IA, Shtessel L, Compton N, Mirza MR and Monk BJ. Progression-free survival and safety at 3.5 years of follow-up: results from the randomised phase 3 PRIMA\/ENGOT-OV26\/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer. Eur J Cancer 2023; 189: 112908.","journal-title":"Eur J Cancer"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"4294","DOI":"10.1200\/JCO.24.00668","article-title":"Atezolizumab combined with platinum and maintenance niraparib for recurrent ovarian cancer with a platinum-free interval > 6 months: ENGOT-OV41\/GEICO 69-O\/ANITA phase III trial","volume":"42","author":"Gonz&#xE1","year":"2024","unstructured":"González-Martín A, Rubio MJ, Heitz F, Depont Christensen R, Colombo N, Van Gorp T, Romeo M, Ray-Coquard I, Gaba L, Leary A, De Sande LM, Lebreton C, Redondo A, Fabbro M, Barretina Ginesta MP, Follana P, Pérez-Fidalgo JA, Rodrigues M, Santaballa A, Sabatier R, Bermejo-Pérez MJ, Lotz JP, Pardo B, Marquina G, Sánchez-Lorenzo L, Quindós M, Estévez-García P, Guerra Alía E, Manso L, Casado V, Kommoss S, Tognon G, Henry S, Bruchim I, Oaknin A and Selle F. Atezolizumab combined with platinum and maintenance niraparib for recurrent ovarian cancer with a platinum-free interval > 6 months: ENGOT-OV41\/GEICO 69-O\/ANITA phase III trial. J Clin Oncol 2024; 42: 4294-4304.","journal-title":"J Clin Oncol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1007\/s11684-024-1083-5","article-title":"First evidence of olaparib maintenance therapy in patients with newly diagnosed homologous recombination deficient positive\/BRCA wild-type ovarian cancer: real-world multicenter study","volume":"18","author":"Li","year":"2024","unstructured":"Li J, Chen Y, He M, Chen X, Wen H, Kang Y, Liu K, Lou G, Wang X, Wen Q, Wang L and Lin Z. First evidence of olaparib maintenance therapy in patients with newly diagnosed homologous recombination deficient positive\/BRCA wild-type ovarian cancer: real-world multicenter study. Front Med 2024; 18: 1026-1034.","journal-title":"Front Med"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"4305","DOI":"10.1200\/JCO.24.00683","article-title":"Cediranib and olaparib combination compared with cediranib or olaparib alone, or chemotherapy in platinum-resistant or primary platinum-refractory ovarian cancer: NRG-GY005","volume":"42","author":"Lee","year":"2024","unstructured":"Lee JM, Brady MF, Miller A, Moore RG, MacKay H, McNally L, Lea J, Street D, Lheureux S, McDonald ME, Duska LR, Cantuaria G, Kavecansky J, Leath CA 3rd, Powell M, Cadungog MG, Rose PG, Kim YM, Huang HQ, Provencher M, Wenzel LB, Bookman MA, Kohn EC and Secord AA. Cediranib and olaparib combination compared with cediranib or olaparib alone, or chemotherapy in platinum-resistant or primary platinum-refractory ovarian cancer: NRG-GY005. J Clin Oncol 2024; 42: 4305-4316.","journal-title":"J Clin Oncol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1186\/s12885-024-13324-0","article-title":"New prognostic index for neoadjuvant chemotherapy outcome in patients with advanced high-grade serous ovarian cancer","volume":"24","author":"Huo","year":"2024","unstructured":"Huo C, Wu B, Ye D, Xu M, Ma S, Cheng A, Liu Y, Huang C, Zhang Y, Lin Z, Li B and Lu H. New prognostic index for neoadjuvant chemotherapy outcome in patients with advanced high-grade serous ovarian cancer. BMC Cancer 2024; 24: 1536.","journal-title":"BMC Cancer"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Friedlander M, Lee YC and Tew WP. Managing adverse effects associated with poly (ADP-ribose) polymerase inhibitors in ovarian cancer: a synthesis of clinical trial and real-world data. Am Soc Clin Oncol Educ Book 2023; 43: e390876.","DOI":"10.1200\/EDBK_390876"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"20601","DOI":"10.1038\/s41598-022-23726-4","article-title":"A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for niraparib","volume":"12","author":"Guo","year":"2022","unstructured":"Guo M, Shu Y, Chen G, Li J and Li F. A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for niraparib. Sci Rep 2022; 12: 20601.","journal-title":"Sci Rep"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1390820","DOI":"10.3389\/fonc.2024.1390820","article-title":"Real-world TRAE association between niraparib and platinum-based chemotherapy","volume":"14","author":"Wang","year":"2024","unstructured":"Wang L, Zhou J, Wang H, Han W and Fang C. Real-world TRAE association between niraparib and platinum-based chemotherapy. Front Oncol 2024; 14: 1390820.","journal-title":"Front Oncol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"869","DOI":"10.21037\/atm-21-2252","article-title":"Real-world hematological adverse events in Chinese patients with advanced ovarian cancer treated with an individualized starting dose of niraparib","volume":"9","author":"Wang","year":"2021","unstructured":"Wang J and Zhu J. Real-world hematological adverse events in Chinese patients with advanced ovarian cancer treated with an individualized starting dose of niraparib. Ann Transl Med 2021; 9: 869.","journal-title":"Ann Transl Med"}],"container-title":["American Journal of Cancer Research"],"original-title":[],"link":[{"URL":"https:\/\/e-century.us\/files\/ajcr\/15\/5\/ajcr0163728.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T02:00:09Z","timestamp":1766023209000},"score":1,"resource":{"primary":{"URL":"https:\/\/e-century.us\/files\/ajcr\/15\/5\/ajcr0163728.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":33,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.62347\/fgly8019","relation":{},"ISSN":["2156-6976"],"issn-type":[{"type":"electronic","value":"2156-6976"}],"subject":[],"published":{"date-parts":[[2025]]}}}